Manan Fariza Aina Abd, Yusof Nor Azah, Abdullah Jaafar, Mohammad Faruq, Nurdin Armania, Yazan Latifah Saiful, Khiste Sachin K, Al-Lohedan Hamad A
Institute of Advanced Technology, Universiti Putra Malaysia, Serdang 43400, Selangor, Malaysia.
Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang 43400, Selangor, Malaysia.
Pharmaceutics. 2021 Aug 31;13(9):1379. doi: 10.3390/pharmaceutics13091379.
Nanotechnology-based drug delivery systems are an emerging technology for the targeted delivery of chemotherapeutic agents in cancer therapy with low/no toxicity to the non-cancer cells. With that view, the present work reports the synthesis, characterization, and testing of Mn:ZnS quantum dots (QDs) conjugated chitosan (CS)-based nanocarrier system encapsulated with Mitomycin C (MMC) drug. This fabricated nanocarrier, MMC@CS-Mn:ZnS, has been tested thoroughly for the drug loading capacity, drug encapsulation efficiency, and release properties at a fixed wavelength (358 nm) using a UV-Vis spectrophotometer. Followed by the physicochemical characterization, the cumulative drug release profiling data of MMC@CS-Mn:ZnS nanocarrier (at pH of 6.5, 6.8, 7.2, and 7.5) were investigated to have the highest release of 56.48% at pH 6.8, followed by 50.22%, 30.88%, and 10.75% at pH 7.2, 6.5, and 7.5, respectively. Additionally, the drug release studies were fitted to five different pharmacokinetic models including pesudo-first-order, pseudo-second-order, Higuchi, Hixson-Crowell, and Korsmeyers-Peppas models. From the analysis, the cumulative MMC release suits the Higuchi model well, revealing the diffusion-controlled mechanism involving the correlation of cumulative drug release proportional to the function square root of time at equilibrium, with the correlation coefficient values (R) of 0.9849, 0.9604, 0.9783, and 0.7989 for drug release at pH 6.5, 6.8, 7.2, and 7.5, respectively. Based on the overall results analysis, the formulated nanocarrier system of MMC synergistically envisages the efficient delivery of chemotherapeutic agents to the target cancerous sites, able to sustain it for a longer time, etc. Consequently, the developed nanocarrier system has the capacity to improve the drug loading efficacy in combating the reoccurrence and progression of cancer in non-muscle invasive bladder diseases.
基于纳米技术的药物递送系统是一种新兴技术，可在癌症治疗中实现化疗药物的靶向递送，对非癌细胞的毒性低/无毒性。基于此观点，本研究报告了负载丝裂霉素C（MMC）药物的锰掺杂硫化锌量子点（QDs）共轭壳聚糖（CS）基纳米载体系统的合成、表征及测试。使用紫外可见分光光度计，对制备的纳米载体MMC@CS-Mn:ZnS在固定波长（358nm）下的载药量、药物包封率和释放特性进行了全面测试。在进行理化表征之后，研究了MMC@CS-Mn:ZnS纳米载体在pH值为6.5、6.8、7.2和7.5时的累积药物释放曲线数据，发现在pH 6.8时释放率最高，为56.48%，其次在pH 7.2、6.5和7.5时分别为50.22%、30.88%和10.75%。此外，药物释放研究拟合了五种不同的药代动力学模型，包括伪一级、伪二级、Higuchi、Hixson-Crowell和Korsmeyers-Peppas模型。分析结果表明，MMC的累积释放很好地符合Higuchi模型，揭示了扩散控制机制，即累积药物释放与平衡时时间的平方根函数相关，在pH 6.5、6.8、7.2和7.5时药物释放的相关系数值（R）分别为0.9849、0.9604、0.9783和0.7989。基于总体结果分析，所制备的MMC纳米载体系统协同设想了将化疗药物有效递送至目标癌灶，并能够长时间维持这种递送等。因此，所开发的纳米载体系统有能力提高药物负载效果，以对抗非肌肉浸润性膀胱疾病中癌症的复发和进展。
